FDA Adds Warning Label to RSV Vaccines Abrysvo and Arexvy
MONDAY, Jan. 13, 2025 -- The U.S. Food and Drug Administration now requires and has approved safety labeling changes to the prescribing information for the Abrysvo (Pfizer) and Arexvy (GlaxoSmithKline) respiratory syncytial virus (RSV) vaccines to include warnings and precautions about the risk for Guillain-Barré syndrome (GBS).
For each vaccine, postmarketing observational studies suggest an increased risk of GBS during the 42 days following vaccination.
Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk. Abrysvo has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older, as well as individuals aged 18 to 59 years at increased risk. Abrysvo is also approved for pregnant individuals at 32 through 36 weeks of gestational age for the prevention of lower respiratory tract disease caused by RSV in infants from birth through 6 months of age.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Read this next
Influenza-Linked Hospitalization Rate High in 2024 to 2025 Flu Season
WEDNESDAY, Sept. 17, 2025 -- The cumulative influenza-associated hospitalization rate for the 2024 to 2025 season surpassed all end-of-season rates during the period beginning...
RSV Vaccine Prevents RSV-Linked Hospitalization Among Older Adults Over Two Seasons
FRIDAY, Sept. 12, 2025 -- The respiratory syncytial virus (RSV) vaccine reduces RSV-associated hospitalization among older adults over two seasons, according to a study published...
Hepatitis B Virus Immunity Linked to Reduced Risk for Diabetes
THURSDAY, Sept. 11, 2025 -- Hepatitis B virus (HBV) immunity in individuals without HBV infection is associated with a reduced risk for diabetes, according to a study published...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.